17c起草视频 strengthens Executive Committee with H茅l猫ne Sicard joining as Chief Development Officer

Marseille, France, July 25, 2024 鈥� 17c起草视频, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of H茅l猫ne Sicard, PhD, as Chief Development Officer.

The appointment of Dr. Sicard comes at a time when the company has selected its lead candidate, DGX-01, a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in the pancreas. DGX-01 is now entering IND-enabling studies. The company鈥檚 novel approach has the potential to become a disease-modifying therapy for type 1 diabetes (T1D), a chronic auto-immune condition that affects millions of people worldwide.

鈥淒r. Sicard has extensive experience in leading teams and projects through progressive phases of development in the biotechnology space. I look forward to the exciting path ahead in fulfilling our vision of regenerating functional pancreatic beta cells, with the ultimate aim of restoring patients鈥� insulin independence,鈥� said Benjamin Charles, CEO of 17c起草视频.

Dr. Sicard brings to 17c起草视频 over 25 years鈥� experience in the development of different drug classes (antibodies, small molecules, cell therapies), across multiple therapeutic areas. She has contributed to transitioning more than ten molecules from preclinical to early clinical stage and also has significant experience in late-stage drug development. H茅l猫ne has actively participated in the creation of several biotech companies, as well as their strategic and structural growth. H茅l猫ne holds a PhD in molecular biology from Toulouse Paul Sabatier University (France).

鈥淚 am thrilled to join 17c起草视频,鈥� said Dr. Sicard. 鈥淚ts lead candidate DGX-01 has shown outstanding efficacy in mouse models of T1D as well as safety in preclinical studies. I look forward to leading the development of this first-in-class disease modifying therapy towards the clinical stage.鈥�

17c起草视频 also welcomes Laetitia Cohen-Tannoudji, as Senior Director, CMC, and Joanna Fares, as Director of Drug Development Sciences. Joanna and Laetitia join 17c起草视频 from Emergence Tx (now a wholly owned subsidiary of Eli Lilly and Company) and before that Innate Pharma. In addition, Renaud Perret joins the team as Director, Administration and Finance. He previously worked at Invectys and before that GSK for 16 years.